In the case of patients with acute coronary syndrome (ACS), international guidelines recommend the combined use of antiplatelets, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB), and statins for the secondary prevention of this condition (3–5). The gene discussed is ACE; the disease is acute coronary syndrome.